In the US, Praluent (alirocumab systemic) is a member of the drug class PCSK9 inhibitors and is used to treat Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Heterozygous and High Cholesterol - Familial Homozygous.
Ingredient matches for Praluent
Alirocumab is reported as an ingredient of Praluent in the following countries:
← International Drug Name Search
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.